Antibody

1,010개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,010 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose (Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose (Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleBaylor College of MedicinePhase 1

GINAKIT cells + Etanercept (GINAKIT cells + Etanercept)

Neuroblastoma · Neuroblastoma

#Neuroblastoma#Antibody#Phase1#monoclonal-antibody#Baylor
Trials 1Status Recruiting
AntibodyLimited DatastaleGeneMedicine Co., Ltd.Phase 2

Part C (GM103 and Pembrolizumab, GM103 and Pembrolizumab (Part C))

Head and Neck Cancer; Malignant Melanoma · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase2#monoclonal-antibody#MalignantMelanoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleCancer Insight, LLCPhase 1

trastuzumab (Herceptin, GP2 peptide + GM-CSF vaccine plus trastuzumab)

Breastcancer · Breastcancer

#Breastcancer#Antibody#Phase1#monoclonal-antibody#Cancer
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 3

GP2013 - A Proposed biosimilar rituximab (GP2013 - A Proposed biosimilar rituximab)

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase3#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleAbbViePhase 3

adalimumab biosimilar (GP2017, GP2017 (adalimumab biosimilar))

Ankylosing Spondylitis · Ankylosing Spondylitis

#AnkylosingSpondylitis#Antibody#Phase3#monoclonal-antibody#AbbVie
Trials 1Status Active
AntibodyLimited DatastaleSandozPhase 3

adalimumab (Humira, GP2017 Adalimumab)

Plaque Type Psoriasis · Plaque Type Psoriasis

#PlaqueTypePsoriasis#Antibody#Phase3#monoclonal-antibody#Sandoz
Trials 1Status Active
AntibodyLimited DatastaleGlenmark Specialty S.A.Phase 1

atezolizumab (Tecentriq, GRC 54276 + Atezolizumab)

Advanced Solid Tumor; Lymphoma · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#monoclonal-antibody#Lymphoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleGlenmark Specialty S.A.Phase 1

pembrolizumab (Keytruda, GRC 54276 + Pembrolizumab)

Advanced Solid Tumor; Lymphoma · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#monoclonal-antibody#Lymphoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleBrightPath BiotherapeuticsPhase 2

pembrolizumab (Keytruda, GRN-1201 + Pembrolizumab)

Metastatic NSCLC · Metastatic NSCLC

#MetastaticNSCLC#Antibody#Phase2#monoclonal-antibody#BrightPath
Trials 1Status Discontinued
AntibodyLimited DatastaleQuantumLeap Healthcare Collabor…Phase 2

GSK 5733584 + Dostarlimab (GSK 5733584 + Dostarlimab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastNeoplasms+2
Trials 1Status Recruiting
AntibodyLimited DatastaleSuzhou Kintor Pharmaceutical In…Phase 2

nivolumab (Opdivo, GT90001 and Nivolumab)

Metastatic Hepatocellular Carcinoma; HCC · Metastatic Hepatocellular Carcinoma

#MetastaticHepatocellularCarcinom#Antibody#Phase2#monoclonal-antibody#HCC+1
Trials 1Status Active
AntibodyLimited DatastaleInsel Gruppe AG, University Hos…Phase 2

durvalumab (Imfinzi, Gemcitabin, Cisplatin and Durvalumab)

Bile Duct Cancer · Bile Duct Cancer

#BileDuctCancer#Antibody#Phase2#monoclonal-antibody#Insel
Trials 1Status Recruiting
AntibodyLimited DatastaleSeoul National University Hospi…Phase 2

nivolumab (Opdivo, Gemcitabine+ nivolumab)

Recurrent or Metastatic Nasopharyngeal Carcinom · Recurrent or Metastatic Nasopharyngeal C

#RecurrentorMetastaticNasopharyng#Antibody#Phase2#monoclonal-antibody#Seoul
Trials 1Status Active
AntibodyLimited DatastaleHenan Provincial People's Hospi…Preclinical

Gene evolution and molecular response under Bevacizumab treatment (Gene evolution and molecular response under Bevacizumab treatment)

Genetic Change · Genetic Change

#GeneticChange#Antibody#Preclinical#monoclonal-antibody#Henan
Trials 1Status Recruiting
AntibodyLimited DatastaleChangchun GeneScience Pharmaceu…Phase 1

Gentulizumab (Gentulizumab)

Solid Tumor; Non-Hodgkin Lymphoma · Solid Tumor

#SolidTumor#Antibody#Phase1#monoclonal-antibody#Non-HodgkinLymphoma+1
Trials 1Status Discontinued

27 / 51 pages

← PreviousNext →